Family history of alcohol dependence and antidepressant response to an N-methyl-D-aspartate antagonist in bipolar depression

被引:55
|
作者
Luckenbaugh, David A. [1 ]
Ibrahim, Lobna [1 ]
Brutsche, Nancy [1 ]
Franco-Chaves, Jose [1 ]
Mathews, Daniel [1 ]
Marquardt, Craig A. [1 ]
Cassarly, Christy [1 ]
Zarate, Carlos A., Jr. [1 ]
机构
[1] NIMH, Expt Therapeut & Pathophysiol Branch, Div Intramural Res Program, US Dept HHS,NIH, Bethesda, MD 20892 USA
基金
美国国家卫生研究院;
关键词
alcohol; bipolar disorder; depression; family history; ketamine; N-methyl-d-aspartate; predictors of response; ADD-ON TRIAL; AFFECTIVE-DISORDER; SUBSTANCE-ABUSE; RATING-SCALE; REPLICATION; KETAMINE; IMPACT; FUTURE;
D O I
10.1111/bdi.12003
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Luckenbaugh DA, Ibrahim L, Brutsche N, Franco-Chaves J, Mathews D, Marquardt CA, Cassarly C, Zarate CA Jr. Family history of alcohol dependence and antidepressant response to an N-methyl-d-aspartate antagonist in bipolar depression. Bipolar Disord 2012: 14: 880887. Published 2012. This article is a U.S. Government work and is in the public domain in the USA. Objectives: Both ketamine and ethanol are N-methyl-d-aspartate (NMDA) receptor antagonists. Ketamine has rapid antidepressant properties in major depressive disorder (MDD) as well as bipolar depression. In individuals with MDD, a positive family history of alcohol dependence (FHP) was associated with greater improvement in depressive symptoms after ketamine administration compared to individuals whose family history of alcohol dependence was negative (FHN). This study investigated whether FHP influences ketamines antidepressant and perceptual effects in individuals with bipolar depression. Methods: A post hoc analysis was conducted on 33 subjects with DSMIV bipolar disorder (BD) type I or II depression pooled from two previously published studies. All subjects had undergone a double-blind, randomized, crossover trial of a single intravenous infusion of ketamine (0.5 mg/kg) combined with lithium or valproate therapy. Subjects were rated at baseline; at 40, 80, 120, and 230 min; and at days 1, 2, 3, 7, 10, and 14 post-infusion. The primary outcome measure was Montgomery-angstrom sberg Depression Rating Scale (MADRS) scores. Patients were categorized as FHP when they reported at least one first-degree relative with alcohol dependence. Measures of psychosis, dissociation, and dysphoria were also collected. Results: After ketamine infusion, subjects with FHP showed significantly greater improvement on MADRS scores than FHN subjects. In addition, patients with FHP had attenuated psychotomimetic and dissociative scores compared to FHN patients. Conclusions: FHP appears to predict a more sustained antidepressant response to ketamine in individuals with BD. Family history of alcoholism may be an important consideration in the development of glutamatergic-based therapies for depression.
引用
收藏
页码:880 / 887
页数:8
相关论文
共 50 条
  • [21] PENTAMIDINE IS AN N-METHYL-D-ASPARTATE RECEPTOR ANTAGONIST AND IS NEUROPROTECTIVE INVITRO
    REYNOLDS, IJ
    AIZENMAN, E
    JOURNAL OF NEUROSCIENCE, 1992, 12 (03): : 970 - 975
  • [22] REVERSAL OF CHLORPROMAZINE-INDUCED AVOIDANCE DEPRESSION BY THE N-METHYL-D-ASPARTATE ANTAGONIST, DIZOCILPINE, IN MICE
    MELE, A
    BATTAGLIA, M
    SANSONE, M
    JOURNAL OF PHARMACY AND PHARMACOLOGY, 1994, 46 (05) : 390 - 392
  • [23] Exploiting N-Methyl-D-Aspartate Channel Blockade for a Rapid Antidepressant Response in Major Depressive Disorder
    Blier, Pierre
    BIOLOGICAL PSYCHIATRY, 2013, 74 (04) : 238 - 239
  • [24] ON or OFF?: Modulating the N-Methyl-D-Aspartate Receptor in Major Depression
    Chan, Shi Yu
    Matthews, Edward
    Burnet, Philip W. J.
    FRONTIERS IN MOLECULAR NEUROSCIENCE, 2017, 9
  • [25] INHIBITION OF CORTICAL SPREADING DEPRESSION BY N-METHYL-D-ASPARTATE ANTAGONISTS
    MARRANNES, R
    DEPRINS, E
    WILLEMS, R
    WAUQUIER, A
    ARCHIVES INTERNATIONALES DE PHARMACODYNAMIE ET DE THERAPIE, 1987, 290 (01): : 156 - 156
  • [26] Rapid decrease in depressive symptoms with an N-methyl-D-aspartate antagonist in ECT-resistant major depression
    Ibrahim, Lobna
    Diazgranados, Nancy
    Luckenbaugh, David A.
    Machado-Vieira, Rodrigo
    Baumann, Jacqueline
    Mallinger, Alan G.
    Zarate, Carlos A., Jr.
    PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 2011, 35 (04): : 1155 - 1159
  • [27] Effects of the N-methyl-D-Aspartate receptor antagonist dextromethorphan on vibrotactile adaptation
    Stephen E Folger
    Vinay Tannan
    Zheng Zhang
    Jameson K Holden
    Mark Tommerdahl
    BMC Neuroscience, 9
  • [28] THE ANTICONVULSANT MK-801 IS A POTENT N-METHYL-D-ASPARTATE ANTAGONIST
    WONG, EHF
    KEMP, JA
    PRIESTLEY, T
    KNIGHT, AR
    WOODRUFF, GN
    IVERSEN, LL
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1986, 83 (18) : 7104 - 7108
  • [29] BURSTING IN HUMAN EPILEPTOGENIC NEOCORTEX IS DEPRESSED BY AN N-METHYL-D-ASPARTATE ANTAGONIST
    AVOLI, M
    OLIVIER, A
    NEUROSCIENCE LETTERS, 1987, 76 (02) : 249 - 254
  • [30] ATTENUATION OF HIPPOCAMPAL INHIBITION BY A NMDA (N-METHYL-D-ASPARTATE) RECEPTOR ANTAGONIST
    CAPEK, R
    ESPLIN, B
    NEUROSCIENCE LETTERS, 1991, 129 (01) : 145 - 148